

Special Issue

In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research, 2nd Edition

Message from the Guest Editors

Molecular imaging can provide real-time noninvasive visualization, characterization, and quantification of biological processes at the molecular levels in intact living subjects. Nuclear molecular imaging has been receiving significant attention due to its high sensitivity and noninvasive imaging profile. This Special Issue of *Pharmaceuticals* invites both original and review articles related to in vivo nuclear imaging in drug development and pharmacological research, and we welcome submissions of the following topics: (1) identify and validate in vivo biomarkers by nuclear molecular imaging; (2) evaluation of on-target and off-target effects, receptor occupancy, and biodistribution information of the radiotracers; (3) in vivo biorthogonal reaction involved radioisotopes to probe mechanism of diseases; (4) determine the pharmacokinetic, pharmacodynamic, and metabolic profiles; (5) dosimetry studies, kinetic modeling of radiotracers in pre-clinical research and clinical investigation; (6) bench-to-bedside clinical translation of radiotracers.

Guest Editors

Dr. Xuyi Yue

Department of Radiology, Diagnostic and Research PET/MR Center, Nemours Children's Health, Wilmington, DE 19803, USA

Dr. Kiran Kumar Solingapuram Sai

Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

Deadline for manuscript submissions

closed (30 December 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/145297

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)